SHC
AI MemoPost-earnings T+3Sotera Health
As of 2026-11-06/Post-earnings T+3/Confidence medium
Data freshness
AI Memo
As of 2026-11-06 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Action
—
Confidence
medium
Horizon
—
Key catalyst
European medical-device demand and 2027 outlook • 2027-02-28
Base target: $16 / p=45% prob
Biggest risk
The beat did not translate into a guidance raise, and management described European customer softness extending into Q4. After the print, JPMorgan cut its target from $17 to $15 while retaining Underweight, and Barclays cut its target from $22 to $20 while retaining Overweight; BMO and RBC reportedly reiterated $22 and $24 targets. The revisions are mixed, not a broad upgrade signal. Sources: https://stockanalysis.com/stocks/shc/forecast/; https://www.benzinga.com/quote/SHC/price-targets
Invalidation
Break below $13 or thesis failure.
What would change my mind?
Q3 adjusted EPS and revenue exceeded the reported consensus, Sterigenics and Nelson Labs posted 8.2% and 9.2% constant-currency revenue growth, and leverage reached 2.9x. If European demand stabilizes and 2027 capital spending falls as management expects, cash generation could support recovery. [#SEC-8K-2026-11-03] [#EARNINGS-TRANSCRIPT-2026Q3] Sources: https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-reports-solid-third-quarter-and-year-date-2026; https://stockanalysis.com/stocks/shc/transcripts/726351-q3-2026/
Research note
Recommendation
—
Confidence
medium
As of
2026-11-06
Base target
$16
p=45%
Bull target
$20
p=25%
Bear target
$13
p=30%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- Cash generation versus investment and debt
- Q3 adjusted EPS and revenue exceeded the reported consensus, Sterigenics and Nelson Labs posted 8.2% and 9.2% constant-currency revenue growth, and leverage reached 2.9x.
- If European demand stabilizes and 2027 capital spending falls as management expects, cash generation could support recovery.
BearKey bullets
- Ethylene-oxide litigation and supply or regulatory requirements could produce adverse outcomes or execution costs.
- [#EARNINGS-TRANSCRIPT-2026Q3] [#SEC-8K-2026-11-03] Sources: https://stockanalysis.com/stocks/shc/transcripts/726351-q3-2026/; https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-reports-solid-third-quarter-and-year-date-2026
- European medical-device customer softness may persist beyond the demand assumptions embedded in reaffirmed guidance.
WatchKey bullets
- European medical-device demand and 2027 outlook
Summary
High-level snapshot
Recommendation
-
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
Post-earnings T+3
Base case: $16 (p=45%)
Target spread vs base: +23% / -21%
Scenario probabilities
Bull Target: $20 (p=25%)Base Target: $16 (p=45%)Bear Target: $13 (p=30%)
Commentary
The company reports a November 2 close of $17.74, a November 3 post-earnings close of $16.03, and a November 5 close of $15.87—about 10.5% below the pre-release close, so the initial selloff had not reversed by T+2. Trusted coverage linked the drop to European demand concerns and unchanged guidance despite a reported revenue/EPS beat. Post-print target cuts from JPMorgan and Barclays contrast with reiterated targets elsewhere. The numerical sentiment fields are unavailable-data placeholders, not measured neutral readings; social, options, short-interest and employee scores were not established. Sources: https://investors.soterahealth.com/stock-info/historical-price-lookup; https://www.investing.com/news/stock-market-news/why-is-sotera-health-stock-sliding-today-93CH-4996335; https://stockanalysis.com/stocks/shc/forecast/
As of 2026-11-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
Q3 adjusted EPS and revenue exceeded the reported consensus, Sterigenics and Nelson Labs posted 8.2% and 9.2% constant-currency revenue growth, and leverage reached 2.9x. If European demand stabilizes and 2027 capital spending falls as management expects, cash generation could support recovery. [#SEC-8K-2026-11-03] [#EARNINGS-TRANSCRIPT-2026Q3] Sources: https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-reports-solid-third-quarter-and-year-date-2026; https://stockanalysis.com/stocks/shc/transcripts/726351-q3-2026/
Bear Case
The beat did not translate into a guidance raise, and management described European customer softness extending into Q4. After the print, JPMorgan cut its target from $17 to $15 while retaining Underweight, and Barclays cut its target from $22 to $20 while retaining Overweight; BMO and RBC reportedly reiterated $22 and $24 targets. The revisions are mixed, not a broad upgrade signal. Sources: https://stockanalysis.com/stocks/shc/forecast/; https://www.benzinga.com/quote/SHC/price-targets
Drivers
Scannable catalysts and supporting factors
- Cash generation versus investment and debt
Scenarios
Bull Target (Scenario probability)
$20 / p=25% prob
Base Target (Scenario probability)
$16 / p=45% prob
Bear Target (Scenario probability)
$13 / p=30% prob
Analysis 2026-11-06 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
News Sentiment (30d)
0.00
Social Sentiment (7d)
0.00
Events
Other notable items detected
- EVENT2027-02-28European medical-device demand and 2027 outlookDespite Q3 adjusted EPS of $0.29 versus a reported $0.27 consensus and revenue of $324.9 million versus $319.8 million, management reaffirmed rather than raised FY2026 growth guidance. On the earnings call, management said European medical-device customer softness began in mid-to-late Q3 and that Sterigenics Q4 revenue should be roughly flat sequentially. The next outlook is the key test of whether softness persists into 2027; February is management's indicated timing, not an announced earnings date. [#SEC-8K-2026-11-03] [#EARNINGS-TRANSCRIPT-2026Q3] Sources: https://www.sec.gov/Archives/edgar/data/1822479/000182247926000055/november32026-ex991.htm; https://stockanalysis.com/stocks/shc/transcripts/726351-q3-2026/; consensus: https://www.investing.com/news/stock-market-news/why-is-sotera-health-stock-sliding-today-93CH-4996335Prob 65.00% • Move -7.00% • Priced-in 60.00%
- EVENT2027-02-28Nordion Co-60 harvest timingNordion's Q3 constant-currency revenue fell 11.5% because of expected Co-60 harvest scheduling, while nine-month revenue was up 6.2% on that basis. Subsequent harvest timing and volume, rather than a straight-line extrapolation of Q3, will determine whether the segment supports FY2026 delivery. [#SEC-8K-2026-11-03] Source: https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-reports-solid-third-quarter-and-year-date-2026Prob 55.00% • Move 4.00% • Priced-in 55.00%
- EVENT2027-04-30Ethylene-oxide litigation milestonesManagement cited a Georgia appellate-decision deadline in spring 2027 and first California trials scheduled for January and April 2027. Outcomes and timing are uncertain, but adverse developments could outweigh operating progress. [#EARNINGS-TRANSCRIPT-2026Q3] Source: https://stockanalysis.com/stocks/shc/transcripts/726351-q3-2026/Prob 50.00% • Move -6.00% • Priced-in 50.00%
Short-term Catalysts
Next few weeks
No short-term catalysts
Long-term Catalysts
Months to a year
- Cash generation versus investment and debt2027-06-30Q3 operating cash flow was $111 million and net leverage improved to 2.9x, but total debt remained $2.2 billion. Management expects capital spending to step down in 2027, without quantifying the amount yet. Demonstrated free cash flow and further deleveraging would strengthen the case; timing is an assessment, not a company milestone. [#SEC-8K-2026-11-03] [#EARNINGS-TRANSCRIPT-2026Q3] Sources: https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-reports-solid-third-quarter-and-year-date-2026; https://stockanalysis.com/stocks/shc/transcripts/726351-q3-2026/Prob 55% • Move 5% • Priced-in 45%
Risks
- Ethylene-oxide litigation and supply or regulatory requirements could produce adverse outcomes or execution costs. [#EARNINGS-TRANSCRIPT-2026Q3] [#SEC-8K-2026-11-03] Sources: https://stockanalysis.com/stocks/shc/transcripts/726351-q3-2026/; https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-reports-solid-third-quarter-and-year-date-2026
- European medical-device customer softness may persist beyond the demand assumptions embedded in reaffirmed guidance. [#EARNINGS-TRANSCRIPT-2026Q3] https://stockanalysis.com/stocks/shc/transcripts/726351-q3-2026/
- Nordion revenue is sensitive to Co-60 harvest timing; Nelson Labs' Q3 segment-income growth lagged revenue growth because of business mix. [#SEC-8K-2026-11-03] https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-reports-solid-third-quarter-and-year-date-2026
- Total debt of $2.2 billion and planned FY2026 capital spending of $200 million–$225 million constrain financial flexibility despite improving leverage. [#SEC-8K-2026-11-03] https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-reports-solid-third-quarter-and-year-date-2026
Peers
| Symbol | Summary |
|---|---|
| STE | STERIS's Applied Sterilization Technologies segment provides contract sterilization and laboratory testing to medical-device and pharmaceutical manufacturers, making it a direct operating comparison for parts of Sotera. STERIS's broader consolidated business is not a clean valuation peer. Source: https://www.sec.gov/Archives/edgar/data/1757898/000162828026039136/ste-20260331.htm |
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-11-06